Glaukos

GKOS · NYSE

$173.43+$6.47 (+3.88%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $166.96

Latest news

NewsOct 9, 12:49 PM ETVandana Singh
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy
Press releaseOct 9, 7:00 AM ETBusiness Wire
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery
NewsOct 8, 12:49 PM ETVandana Singh
Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal
Press releaseOct 8, 7:00 AM ETBusiness Wire
Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases
Press releaseOct 7, 4:05 PM ETBusiness Wire
Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus
Press releaseOct 7, 7:00 AM ETBusiness Wire
Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28
Press releaseSep 23, 7:00 AM ETBusiness Wire
Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus
Press releaseAug 19, 7:00 AM ETBusiness Wire
Glaukos Announces Participation in Wells Fargo Healthcare Conference
Press releaseJul 29, 4:05 PM ETBusiness Wire
Glaukos Announces Second Quarter 2026 Financial Results
Press releaseJul 27, 7:00 AM ETBusiness Wire
Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt
Press releaseJul 8, 7:00 AM ETBusiness Wire
Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29
Press releaseJun 25, 7:00 AM ETBusiness Wire
Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis
Press releaseMay 12, 7:00 AM ETBusiness Wire
Glaukos Announces Participation in Upcoming Investor Conferences
NewsApr 30, 1:05 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
NewsApr 30, 8:06 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
NewsApr 29, 5:06 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
Press releaseApr 29, 4:05 PM ETBusiness Wire
Glaukos Announces First Quarter 2026 Financial Results
NewsApr 29, 7:11 AM ET
Earnings Scheduled For April 29, 2026
Press releaseApr 16, 7:00 AM ETBusiness Wire
Glaukos Announces the Release of its 2025 Sustainability Report
Press releaseApr 15, 4:05 PM ETBusiness Wire
Glaukos Receives Permanent J-code for Epioxa™
Press releaseApr 8, 7:00 AM ETBusiness Wire
Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29
Press releaseApr 6, 7:00 AM ETBusiness Wire
Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Press releaseMar 19, 7:00 AM ETBusiness Wire
Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care
NewsFeb 24, 4:05 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
NewsFeb 18, 10:18 AM ETAvi Kapoor
Wingstop Posts Upbeat Q4 Earnings, Joins Caesars Entertainment, Garmin, Sabre And Other Big Stocks Moving Higher On Wednesday
NewsFeb 18, 9:34 AM ETAvi Kapoor
These Analysts Boost Their Forecasts On Glaukos Following Q4 Results
NewsFeb 18, 7:00 AM ET
Expert Outlook: Glaukos Through The Eyes Of 10 Analysts
Press releaseFeb 17, 4:05 PM ETBusiness Wire
Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results
NewsFeb 16, 11:02 AM ET
Exploring Glaukos's Earnings Expectations
Press releaseJan 28, 7:00 AM ETBusiness Wire
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
Press releaseJan 20, 7:00 AM ETBusiness Wire
Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17
Press releaseJan 13, 4:05 PM ETBusiness Wire
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance
Press releaseDec 16, 7:00 AM ETBusiness Wire
Glaukos Announces Participation in J.P. Morgan Healthcare Conference
Press releaseNov 3, 7:00 AM ETBusiness Wire
Glaukos Announces Participation in Upcoming Investor Conferences
NewsOct 30, 8:08 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Press releaseOct 29, 4:05 PM ETBusiness Wire
Glaukos Announces Third Quarter 2025 Financial Results

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy

Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery

Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal

Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases

Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus

Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28

Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus

Glaukos Announces Participation in Wells Fargo Healthcare Conference

Glaukos Announces Second Quarter 2026 Financial Results

Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt

Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29

Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis

Glaukos Announces Participation in Upcoming Investor Conferences

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

12 Health Care Stocks Moving In Wednesday's After-Market Session

Glaukos Announces First Quarter 2026 Financial Results

Earnings Scheduled For April 29, 2026

Glaukos Announces the Release of its 2025 Sustainability Report

Glaukos Receives Permanent J-code for Epioxa™

Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29

Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

12 Health Care Stocks Moving In Tuesday's After-Market Session

Wingstop Posts Upbeat Q4 Earnings, Joins Caesars Entertainment, Garmin, Sabre And Other Big Stocks Moving Higher On Wednesday

These Analysts Boost Their Forecasts On Glaukos Following Q4 Results

Expert Outlook: Glaukos Through The Eyes Of 10 Analysts

Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results

Exploring Glaukos's Earnings Expectations

Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR

Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance

Glaukos Announces Participation in J.P. Morgan Healthcare Conference

Glaukos Announces Participation in Upcoming Investor Conferences

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Glaukos Announces Third Quarter 2025 Financial Results